The results from a pilot study of the PAN Study in cirrhotic patients have been published by authors from Owlstone Medical, Cambridge University Hospitals NHS Foundation Trust and the University of Cambridge in ‘Clinical and Translational Hepatology’. This research successfully demonstrates the use of exhaled limonene as a breath biomarker to measure liver function and stage liver disease.
This data validates Owlstone’s exogenous volatile organic compound probe approach for breath-based diagnostic test development that is being applied in the PAN Study. These results are one output of the successful collaboration between Owlstone Medical, the Cancer Research UK Cambridge Centre and Cambridge University Hospitals NHS Foundation Trust.
Dr. Victoria Snowdon, Consultant, Transplant Hepatology, Cambridge University Hospitals commented: “The burden of liver disease is high and continues to grow, and so assessment of liver function is essential for determining prognosis and establishing effective treatment. The findings of this study suggest that a breath test could non-invasively help us determine liver function, helping to monitor patients with liver disease from an early stage and optimize treatment.
For more details see the press release here.